Darovasertib
Darovasertib (LXS196) is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. Darovasertib has the potential for uveal melanoma research[1][2].
Product Specifications
CAS Number
1874276-76-2
Product Name Alternative
LXS196; IDE196
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
PKC
Type
Reference compound
Related Pathways
Epigenetics; TGF-beta/Smad
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LXS196.html
Purity
99.18
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
NC1=C(C(NC2=C(N3CCC(C)(N)CC3)C=CC=N2)=O)N=C(C4=NC=CC=C4C(F)(F)F)C=N1
Molecular Formula
C22H23F3N8O
Molecular Weight
472.47
Precautions
H302, H315, H319
References & Citations
[1]Protein Kinase C Inhibitor LXS196|[2]US20180179181.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PKCα; PKCθ
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LS009862-100ug 100 µg
TRAP100 (MED24) (NM_014815) Human Over-expression Lysate
Sign In for Pricing
View Details 
bs-15013R-BF647-TR 20 µL
C1orf124 Polyclonal Antibody, AbBy Fluor™ 647 Conjugated
Sign In for Pricing
View Details